Thank you, Chair.
Thank you very much, Ms. Hillman, for the broad overview of the TPP and how complex it is.
You spoke to just how diverse our market is here in Canada in all sectors. For many of those the jurisdiction is provincial.
I want to ask a number of questions, but one is with respect to IP.
Drug costs make up about 14% or 15% of the health care costs here in Ontario, and the health care budget is about 50% of the overall budget, so you're looking at about 7% of our budget here in Ontario. How would the increased costs because of the IP extension, the patent extensions, affect a province such as Ontario, or any other province across the country?